FHTX

Foghorn TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$3.00

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$1.80

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.90

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-14

AI commentary

News tone is sharply negative following the October 1 announcement. FHTX closed at $1.85 on October 13, below the approximately $2.01 level reported during the October 2 sell-off; this suggests the initial reaction had not reversed. Wedbush's downgrade and target cut corroborate a thesis reset, but broader forward-estimate revisions are unavailable. The numerical news score is qualitative; zero-valued social, options, short-interest and employee fields denote unavailable data, not neutral readings. The positive deterministic return prior is outweighed by the confirmed clinical and collaboration setback. Historical prices October 2 market reaction RTTNews downgrade record

RankAlpha Sentiment Codex - 2026-10-14

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-11-14catalystFHD-909 and Lilly collaboration setbackHigh impact

After reviewing Phase 1 data, Foghorn and Lilly decided not to advance FHD-909 into dose expansion; further collaboration activity is not anticipated. The company said target engagement and safety did not translate into sufficient efficacy. The setback is known, but its effect on the remaining pipeline may continue to be repriced [#8-K-2026-10-01]. SEC filing Company release filed as Exhibit 99.1

2026-12-31eventWorkforce reduction and runway executionMedium impact

Foghorn expects to substantially complete an approximately 40% workforce reduction in Q4 2026 and incur about $2.3 million of associated cash charges. It projects that reprioritization will extend its cash runway into the second half of 2029; subsequent spending disclosures will test that projection [#8-K-2026-10-01]. SEC filing Company release filed as Exhibit 99.1

2027-12-31catalystWholly owned EP300 degrader IND targetHigh impact

Foghorn's August 2026 update targeted an IND in 2027 for its selective EP300 degrader. The program remains preclinical, and the timing needs reconfirmation after October's reprioritization; IND-enabling progress is the relevant milestone, not assumed clinical efficacy [#SEC-8K-2026-08-06]. SEC earnings exhibit

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-14 • Updated nightlySource: Internal modelMethodology